title: Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2.
abstract: An inverse relationship between Parkinson's disease (PD) and cancer has been described. However, the association between cancers and genetic forms of PD, in particular the R1441G mutation in the LRRK2 gene, is not well known. The objective of this work was to analyze cancer prevalence in PD patients with R1441G or G2019S mutations in LRRK2, and in idiopathic PD (iPD). A total of 732 patients with PD (70 and 25 carriers of R1441G or G2019S mutations, respectively), and 177 controls, were linked using a population-based cancer registry of the Spanish province of Gipuzkoa. Cancer prevalence was not significantly higher in PD-G2019S carriers (20%) than in PD-R1441G carriers (14.3%), iPD (13.8%), or controls (12.5%). With the exception of a high prevalence of hematological cancers (crude odds ratio of 7.1) in the R1441G group, specific cancer types were not increased in PD mutation carriers. In both the carrier and iPD groups, cancers were diagnosed after the onset of PD. PD patients had a similar prevalence of cancer to control subjects. There was no increased association between G2019S or R1441G mutations and any type of cancer. Although there was a higher prevalence of hematological cancers in the R1441G group, the low number of such cancers overall makes this finding of uncertain significance. There was a slightly higher but not statistically significant prevalence of non-skin cancers in the G2019S group, suggesting that further study to evaluate the association should be undertaken prior to ascribing an increased cancer risk to this population.
authors.affiliation: Department of Neurology, University Hospital Donostia, San Sebastián, Spain; Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED), San Sebastián, Spain; Neurosciences Area, Biodonostia Institute, San Sebastián, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Ruiz-Martínez
authors.forename: Patricia
authors.initials: P
authors.lastname: de la Riva
authors.forename: Maria C
authors.initials: MC
authors.lastname: Rodríguez-Oroz
authors.forename: Elisabet
authors.initials: E
authors.lastname: Mondragón Rezola
authors.forename: Alberto
authors.initials: A
authors.lastname: Bergareche
authors.forename: Ana
authors.initials: A
authors.lastname: Gorostidi
authors.forename: Belen
authors.initials: B
authors.lastname: Gago
authors.forename: Ainara
authors.initials: A
authors.lastname: Estanga
authors.forename: Nerea
authors.initials: N
authors.lastname: Larrañaga
authors.forename: Cristina
authors.initials: C
authors.lastname: Sarasqueta
authors.forename: Adolfo
authors.initials: A
authors.lastname: López de Munain
authors.forename: José F
authors.initials: JF
authors.lastname: Martí Massó
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D004252:DNA Mutational Analysis; D005260:Female; D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D010300:Parkinson Disease / Q000453:epidemiology* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D015995:Prevalence; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*
chemical_list: C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases
keywords: G2019S; LRRK2; Parkinson's disease; R1441G; cancer